FORGE today’s life science innovation into tomorrow's transformative therapeutics
FORGE Life Science was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, FORGE antivirals engage the cell’s intrinsic immunity to defend against infection. FORGE’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine because FORGE products will address the infectious disease condition as opposed to targeting a specific virus-type. Imagine being prescribed a safe, broad-spectrum antiviral, without the risk of acquired drug-resistance, based on symptom presentation, and prior to diagnostic confirmation of infecting virus-type. Our highly-innovative products are early-stage, yet we bring tangible solutions to solve real clinical challenges and unmet medical need.
FORGE has four drug discovery programs applying our broad-spectrum antiviral technology in a uniquely apt way to address clinical challenges currently unmet by traditional virus-targeting strategies: (1) a pan-respiratory infections antiviral with demonstrated effectiveness against seasonal, pandemic, and influenza A and B strains resistant to current drugs; (2) a single pill effective against multiple (opportunistic) infections including herpes virus and polyomavirus infections posing serious complications for immunosuppressed patients receiving organ transplants; (3) a brain-penetrant antiviral to treat viral encephalitis; and (4) a liver infections antiviral targeting HBV and HCMV.
Ensuring successful translation of our drug discovery programs to ultimately address patient needs in the clinic, FORGE has a world-class team with proven track record for innovation and commercialization success. We will pursue a focused business plan maximizing non-dilutive funding with broad pharma partnering opportunities in parallel with internal value creation.